文献速递免疫规划慢病防控与筛查

灭活SARS-CoV-2疫苗接种不干扰Graves病的临床病程:一项观察性队列研究

Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
PubMed 文献 · Vaccine · 2023-08-04

该回顾性研究纳入651例接受随访的Graves病(GD)患者,其中443例接种灭活SARS-CoV-2疫苗、208例未接种,分析接种对甲状腺功能指标及TRAb阳性、甲亢复发风险的影响。结果显示接种组新发TRAb阳性风险显著降低(调整HR=0.22),甲亢复发风险未见增加(调整HR=1.20),结论认为灭活疫苗接种不干扰GD甲亢患者的治疗病程。

要点

  • 接种组新发TRAb阳性风险显著低于未接种组(调整HR=0.22,95%CI 0.10-0.48)。
  • 接种与甲亢复发风险无关(调整HR=1.20,95%CI 0.51-2.83,P=0.678)。
  • 新诊断GD患者接种后达到甲状腺毒症缓解的可能性与未接种者相当。

核心结论

  • 灭活SARS-CoV-2疫苗接种不会干扰Graves病甲亢患者的治疗病程。

研究设计与样本

  • 回顾性观察性队列研究,纳入江原医院随访的651例Graves病患者,其中443例接种灭活SARS-CoV-2疫苗、208例未接种。

主要发现

  • 接种组与未接种组在GD甲亢治疗期间TRAb和fT3中位水平均显著下降。
  • 两组fT4水平均在正常范围内并呈同步下降趋势。
  • 随访期间TSH水平呈上升趋势,但两组间未见显著差异。
  • 除新诊断GD患者外,接种组新发TRAb阳性风险显著低于未接种组(调整HR=0.22;95%CI:0.10-0.48,P<0.001),校正性别、年龄、病程及基线MMI剂量。
  • 接种不太可能成为甲亢复发的危险因素(调整HR=1.20;95%CI:0.51-2.83,P=0.678)。

关键数值与推荐

  • 新发TRAb阳性:接种组 vs 未接种组调整HR=0.22(95%CI:0.10-0.48,P<0.001)。
  • 甲亢复发:接种组 vs 未接种组调整HR=1.20(95%CI:0.51-2.83,P=0.678)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SARS-CoV-2 vaccination has been reported to be associated with the induction of thyroid disorders. To investigate the influence of SARS-CoV-2 vaccination on the disease course of patients who were undergoing treatment for Graves' disease (GD), a total of 651 consecutive GD patients who attended follow-up visits in Jiangyuan Hospital were enrolled in this retrospective study, including 443 inactivated SARS-CoV-2 vaccine recipients and 208 unvaccinated participants. The changes in serum levels of free triiodothyronine (fT3), free thyroxine (fT4), thyroid stimulating hormone (TSH) and TSH receptor antibody (TRAb) were analyzed. Crude and adjusted hazard ratios (HRs) were estimated using Cox regression models to investigate the risks in incident TRAb positivity and hyperthyroidism recurrence following vaccination. The median levels of TRAb and fT3 significantly decreased in both vaccinated and unvaccinated groups during the GD hyperthyroidism treatment. The fT4 levels of both groups were well within normal limits and presented downward trends simultaneously. Although the present study observed an increasing trend of TSH level during follow-up, significant difference was not seen in both vaccinated and unvaccinated groups. Except for newly diagnosed GD patients, vaccinated participants had significantly lower risks of incident TRAb positivity (adjusted HR = 0.22; 95%CI: 0.10-0.48, P < 0.001) after adjusted for sex, age, disease duration and MMI dose at baseline. Besides, vaccination was unlikely to serve as a risk factor for hyperthyroidism recurrence (adjusted HR = 1.20; 95%CI: 0.51-2.83, P = 0.678). Notably, newly diagnosed patients who received vaccination were just as likely to achieve remission of thyrotoxicosis as those not receiving the vaccination at any time. Our results concluded that inactivated SARS-CoV-2 vaccination would not disturb the treatment course among GD hyperthyroidism patients.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xu S, Yu H, Cheng X, et al. Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study. Vaccine. 2023. PMID: 37544826. doi:10.1016/j.vaccine.2023.07.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。